#Switzerland #Zug #APAC #Medison #Francis Wan

Medison Appoints Francis Wan as VP and GM of Asia Pacific

Medison, an innovative leader in biopharmaceutical commercialization, has recently announced a significant appointment aimed at bolstering its operations in the Asia Pacific (APAC) region. Francis Wan, who brings over 20 years of extensive experience in biopharmaceutical leadership, has been named the new Vice President and General Manager for APAC. His appointment signifies a critical step in Medison's strategy to expand its global commercialization platform, particularly in areas with unaddressed healthcare needs.

The Role of Francis Wan in Medison's Strategy

Francis Wan will spearhead Medison's operations and strategic initiatives across APAC, an essential growth market for the company’s innovative therapies. Previously, Wan held prominent roles in leading global healthcare companies, including serving as President of Biogen for the region and managing commercial operations at MSD China. His expertise in oncology and rare diseases, coupled with a deep understanding of the Chinese healthcare ecosystem, equips him to address the complexities of this diverse market.

"Breakthrough therapies are still out of reach for many patients across APAC, creating significant unmet healthcare needs," Wan stated. He emphasizes Medison’s commitment to changing this landscape by ensuring broader access to life-saving treatments.

Wan’s vision aligns with Medison's fundamental belief that every patient deserves timely access to medication, irrespective of their location. His leadership will be paramount in tailoring sustainable solutions for patients with severe and rare conditions in APAC.

Medison's Commitment to Access and Innovation

Founded on the premise of equitable healthcare access, Medison aims to address one of the most pressing challenges in the pharmaceutical industry: enabling patient access to breakthrough therapies. The company has developed a unique global commercialization platform that allows biotechnological firms to efficiently navigate market entry and expansion beyond western regions. It integrates commercial, medical, and operational capabilities to enhance therapeutic accessibility.

Meir Jakobsohn, the Executive Chairman and co-founder of Medison, remarked on Wan's appointment as a pivotal move that reflects their ongoing investment in the APAC region, characterized by immense potential and need for innovative therapies.

"Francis's expertise will help us advance toward our expansion objectives and solidify our position as a leading commercialization company for international markets," Jakobsohn added.

CEO Gil Gurfinkel also highlighted the strategic importance of Wan's role in Medison's global growth journey, showcasing the company's dedication to facilitating faster access to transformative therapies while nurturing partnerships within the region.

Conclusion

In a time where global health equity remains an urgent issue, appointments like Francis Wan’s at Medison reflect a forward-thinking approach to bridging the gaps in healthcare accessibility. With Wan at the helm of operations in APAC, Medison is well-positioned to forge paths that enhance patient access to critical treatments, ultimately leading to improved health outcomes in underserved populations. As Medison continues to innovate in the realm of biopharmaceuticals, its global commercialization platform, coupled with Wan’s rich experience, heralds a promising future for patients across the Asia Pacific region.

For more information about the initiatives at Medison and its strategic progress under Francis Wan, visit their official website at Medison Pharma.